



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

January 30, 2023

Larry Zhang  
Principal Financial Officer  
CASI Pharmaceuticals, Inc.  
9620 Medical Center Drive  
Suite 300  
Rockville, MD 20850

**Re: CASI Pharmaceuticals, Inc.**  
**Form 10-K for the Fiscal Year Ended December 31, 2021**  
**Form 10-Q for the Interim Period Ended September 30, 2022**  
**File No. 000-20713**

Dear Larry Zhang:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences